Hostname: page-component-78c5997874-v9fdk Total loading time: 0 Render date: 2024-11-05T06:40:12.076Z Has data issue: false hasContentIssue false
  • English
  • Français

Seronegative Myasthenia Gravis and Human Immunodeficiency Virus Infection: Response to Intravenous Gamma Globulin and Prednisone

Published online by Cambridge University Press:  18 September 2015

James Strong  and
Douglas W. Zochodne
James Strong
Affiliation:
Department of Clinical Neurosciences, University of Calgary, Calgary.
Douglas W. Zochodne*
Affiliation:
Department of Clinical Neurosciences, University of Calgary, Calgary.
*
University of Calgary, Department of Clinical Neurosciences, Room I82A, 3330 Hospital Drive N.W., Calgary, Alberta, Canada T2N4N1 254
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

There are only rare reports of myasthenia gravis complicating human immunodeficiency virus infection. The role of immunomodulatory therapy is unknown.

Methods:

Case report and literature review.

Results:

The diagnosis of human immunodeficiency virus infection followed that of myasthenia gravis in a 35-year-old man. Clinical and electrophysiological features were diagnostic of generalized myasthenia gravis but two edrophonium chloride tests and acetylcholine receptor antibodies were negative. Prednisone therapy and intravenous gamma globulin were associated with rapid clinical recovery.

Conclusions:

Prednisone therapy and intravenous gamma globulin may be helpful in patients with generalized myasthenia gravis complicating HIV infection.

Type
Original Articles
Information
Canadian Journal of Neurological Sciences , Volume 25 , Issue 3 , August 1998 , pp. 254 - 256
Copyright
Copyright © Canadian Neurological Sciences Federation 1998

References

REFERENCES

1.Bettaieb, A, Oksenhendler, E, Duedari, N, Bierling, P. Cross-reactive antibodies between HIV-gpl20 and platelet gpllla (CD61) in HIV-related immune thrombocytopenic purpura. Clin Exp Immunol 1996; 103: 19–23.CrossRefGoogle Scholar
2.Font, J, Vidal, J, Cervera, R, et al. Lack of relationship between human immunodeficiency virus infection and systemic lupus erythematosus. Lupus 1995; 4: 47–49.CrossRefGoogle ScholarPubMed
3.Gul, A, Inanc, M, Yilmaz, G, et al. Antibodies reactive with HIV-1 antigens in systemic lupus erythematosus. Lupus 1996; 5: 120–122.CrossRefGoogle ScholarPubMed
4.Contreras, G, Green, DF, Pardo, V, Schultz, DR, Bourgoignie, JJ. Systemic lupus erythematosus in two adults with human immunodeficiency virus infection. Am J Kidney Dis 1996; 28: 292–295.CrossRefGoogle ScholarPubMed
5.Fraziano, M, Montesano, C, Lombardi, VR, et al. Epitope specificity of anti-HIV antibodies in human and murine autoimmune diseases. AIDS Res Hum Retroviruses 1996; 12: 491–496.CrossRefGoogle ScholarPubMed
6.Merrill, JE, Graves, MC, Mulder, DG. Autoimmune disease and the nervous system. Biochemical, molecular, and clinical update. West J Med 1992; 156: 639–646.Google ScholarPubMed
7.Authier, FJ, De Grissac, N, Degos, JD, Gherardi, RK. Transient myasthenia gravis during HIV infection. Muscle Nerve 1995; 18: 914–916.CrossRefGoogle ScholarPubMed
8.Martini, L, Vion, P, Le Gangneux, E, Grandpierre, G, Becquet, D. [AIDS and myasthenia: an uncommon association.] Rev Neurol (Paris) 1991; 147: 395–397.Google ScholarPubMed
9.Nath, A, Kerman, RH, Novak, IS, Wolinsky, JS. Immune studies in human immunodeficiency virus infection with myasthenia gravis: a case report. Neurology 1990; 40: 581–583.CrossRefGoogle ScholarPubMed
10.Tiab, M, Letortorec, S, Michelet, C, et al. [Occurrence of myasthenia in HIV infection.] Ann Med Interne (Paris) 1993; 144: 456–462.Google ScholarPubMed
11.Wessel, HB, Zitelli, BJ. Myasthenia gravis associated with human T-cell lymphotropic virus type III infection. Pediatr Neurol 1987; 3: 238–239.CrossRefGoogle ScholarPubMed
12.Wullenweber, M, Schneider, U, Hagenah, R. [Myasthenia gravis in AIDS and neurosyphilis.] Nervenarzt 1993; 64: 273–277.Google ScholarPubMed
13.Verma, A, Berger, J. Myasthenia gravis associated with dual infection of HIV and HTLV-1. Muscle Nerve 1995; 18: 1355–1356.Google Scholar
14.Vittecoq, D, Morel, C, Eymard, B, Bach, JF. Recovery from myasthenia gravis of a patient infected with human immunodeficiency virus. Clin Infect Dis 1992; 15: 379–380.CrossRefGoogle ScholarPubMed
15.Birmanns, B, Brenner, T, Abramsky, O, Steiner, I. Seronegative myasthenia gravis: clinical features, response to therapy and synthesis of acetylcholine receptor antibodies in vitro. J Neurol Sci 1991; 102: 184–189.CrossRefGoogle ScholarPubMed
16.Verma, P, Oger, J. Treatment of acquired autoimmune myasthenia gravis: a topic review. Can J Neurol Sci 1992; 19: 360–375.CrossRefGoogle ScholarPubMed
17.Brunner, NG, Berger, CL, Namba, T, Grab, D. Corticotropin and corticosteroids in generalized myasthenia gravis: comparative studies and role in management. Ann N Y Acad Sci 1976; 274: 577–595.CrossRefGoogle ScholarPubMed
18.Gagnon, S, Boota, AM, Fischl, MA, et al. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A double-blind, placebocontrolled trial. N Engl J Med 1990; 323: 1444–1450.CrossRefGoogle Scholar
19.Wilcox, CM, Schwartz, DA. A pilot study of oral corticosteroid therapy for idiopathic esophageal ulcerations associated with human immunodeficiency virus infection. Am J Med 1992; 93: 131–134.CrossRefGoogle ScholarPubMed